Anastasia Spiliopoulou
Overview
Explore the profile of Anastasia Spiliopoulou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boattini M, Bianco G, Bastos P, Mavromanolaki V, Maraki S, Spiliopoulou A, et al.
Int J Antimicrob Agents
. 2025 Mar;
:107478.
PMID: 40024606
Introduction: Despite being implicated in a wide spectrum of community- and healthcare-acquired infections, anaerobes have not yet been incorporated into systematic surveillance programs in Europe. Methods: We conducted a multicentre...
2.
Lagadinou M, Amerali M, Michailides C, Chondroleou A, Skintzi K, Spiliopoulou A, et al.
Pathogens
. 2025 Jan;
13(12.
PMID: 39770395
: The increased prevalence of antibiotic resistance among Gram-negative bacteria presents a severe public health challenge, leading to increased mortality rates, prolonged hospital stays, and higher medical costs. In Greece,...
3.
Aretha D, Rizopoulou S, Leonidou L, Kefala S, Karamouzos V, Lagadinou M, et al.
Crit Care Res Pract
. 2024 Jul;
2024:7102082.
PMID: 38947882
Introduction: Critically ill COVID-19 patients hospitalized in intensive care units (ICU) are immunosuppressed due to SARSCoV-2-related immunological effects and are administered immunomodulatory drugs. This study aimed to determine whether these...
4.
Marangos M, Ioannou P, Senn L, Spiliopoulou A, Tzalis S, Kolonitsiou F, et al.
Infection
. 2024 Mar;
52(5):1733-1743.
PMID: 38472708
Purpose: Candidemia is associated with high mortality especially in critically ill patients. Our aim was to identify predictors of mortality among critically ill patients with candidemia with a focus on...
5.
Spiliopoulou A, Giannopoulou I, Assimakopoulos S, Jelastopulu E, Bartzavali C, Marangos M, et al.
Trop Med Infect Dis
. 2023 Nov;
8(11).
PMID: 37999622
Multidrug-resistant infections have become a threat for public health worldwide. The aim of the present study was to follow-up resistance patterns of spp. bloodstream isolates in a Tertiary University Hospital...
6.
Drogari-Apiranthitou M, Skiada A, Panayiotides I, Vyzantiadis T, Poulopoulou A, Christofidou M, et al.
J Fungi (Basel)
. 2023 Apr;
9(4).
PMID: 37108880
Mucormycosis has emerged as a group of severe infections mainly in immunocompromised patients. We analysed the epidemiology of mucormycosis in Greece in a multicentre, nationwide prospective survey of patients of...
7.
Spiliopoulou A, Kyriakou G, Georgiou S, Lekkou A, Leonidou L, Militsopoulou M, et al.
Rev Inst Med Trop Sao Paulo
. 2023 Apr;
65:e29.
PMID: 37075336
Acid-fast bacteria can be implicated in skin and soft tissue infections. Diagnostic identification can be challenging or not feasible by routine laboratory techniques, especially if there is no access to...
8.
Spiliopoulou A, Lekkou A, Vrioni G, Leonidou L, Cogliati M, Christofidou M, et al.
J Mycol Med
. 2023 Apr;
33(3):101386.
PMID: 37031651
Introduction: Non-Candida yeasts, although rare, are increasingly encountered and recognized as a growing threat. Methods: Cases of bloodstream infections (BSIs) due to non-Candida yeasts (NCYs) during the last four years...
9.
Papadimitriou-Olivgeris M, Bartzavali C, Karachalias E, Spiliopoulou A, Tsiata E, Siakallis G, et al.
Antibiotics (Basel)
. 2022 Oct;
11(10).
PMID: 36290072
Background: Ceftazidime/avibactam (CZA) is a new option for the treatment of KPC-producing Klebsiella pneumoniae. The aim of this study was to determine resistance patterns and carbapenemase genes among K. pneumoniae...
10.
Siopi M, Papadopoulos A, Spiliopoulou A, Paliogianni F, Abou-Chakra N, Arendrup M, et al.
J Fungi (Basel)
. 2022 Sep;
8(9).
PMID: 36135656
The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days...